1. Home
  2. DVAX vs PZZA Comparison

DVAX vs PZZA Comparison

Compare DVAX & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • PZZA
  • Stock Information
  • Founded
  • DVAX 1996
  • PZZA 1984
  • Country
  • DVAX United States
  • PZZA United States
  • Employees
  • DVAX N/A
  • PZZA N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • PZZA Restaurants
  • Sector
  • DVAX Health Care
  • PZZA Consumer Discretionary
  • Exchange
  • DVAX Nasdaq
  • PZZA Nasdaq
  • Market Cap
  • DVAX 1.2B
  • PZZA 1.5B
  • IPO Year
  • DVAX 2004
  • PZZA 1993
  • Fundamental
  • Price
  • DVAX $10.15
  • PZZA $52.65
  • Analyst Decision
  • DVAX Buy
  • PZZA Buy
  • Analyst Count
  • DVAX 4
  • PZZA 10
  • Target Price
  • DVAX $26.50
  • PZZA $50.00
  • AVG Volume (30 Days)
  • DVAX 1.3M
  • PZZA 1.6M
  • Earning Date
  • DVAX 11-06-2025
  • PZZA 11-06-2025
  • Dividend Yield
  • DVAX N/A
  • PZZA 3.54%
  • EPS Growth
  • DVAX N/A
  • PZZA 8.47
  • EPS
  • DVAX N/A
  • PZZA 2.28
  • Revenue
  • DVAX $316,268,000.00
  • PZZA $2,085,052,000.00
  • Revenue This Year
  • DVAX $23.23
  • PZZA $4.55
  • Revenue Next Year
  • DVAX $16.57
  • PZZA $0.93
  • P/E Ratio
  • DVAX N/A
  • PZZA $22.83
  • Revenue Growth
  • DVAX 26.66
  • PZZA N/A
  • 52 Week Low
  • DVAX $9.20
  • PZZA $30.16
  • 52 Week High
  • DVAX $14.63
  • PZZA $60.75
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 52.96
  • PZZA 63.00
  • Support Level
  • DVAX $9.71
  • PZZA $51.99
  • Resistance Level
  • DVAX $10.12
  • PZZA $53.70
  • Average True Range (ATR)
  • DVAX 0.24
  • PZZA 2.37
  • MACD
  • DVAX 0.02
  • PZZA 0.85
  • Stochastic Oscillator
  • DVAX 66.92
  • PZZA 82.85

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About PZZA Papa John's International Inc.

Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.

Share on Social Networks: